# US 2024/0199548 A1 · Novel compounds useful as sting agonists and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199548 A1
- Document ID: US20240199548A1
- Status: Published application
- Kind: A1
- Application number: 18/283,834
- Filed: 2022-03-25
- Published: 2024-06-20
- Earliest claimed: 2021-03-26
- Applicants: Jacobio Pharmaceuticals Co., Ltd.
- Inventors: Yang YE; Xiuwei LI; Guiqun YANG; Fashun YAN; Yanping WANG; Wei LONG
- Web page: https://patentgrep.com/patent/US20240199548A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07D 209/44: Iso-indoles; Hydrogenated iso-indoles
- A61K 31/4035: Isoindoles, e.g. phthalimide
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Compounds of general Formula S-1, S-2, S-3 and their pharmaceutically acceptable salts, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are synthesis, compositions, and uses of such compounds.

## Claims

### Claim at position 1

1-67. (canceled)

### Claim 68

A compound, or a pharmaceutically acceptable salt, wherein the compound is of general formula I:
or the compound is of general formula II,
or the compound is of general formula III,
each W is independently selected from CR1 or N;
each R1 is independently selected from H, deuterium, halogen, OR6, N(R6)2, COOR6, or C(O)N(R6)2, CN or C1-C6 alkyl; wherein the C1-C6 alkyl is optionally substituted with one or more deuterium, halogen, OR6, N(R6)2, COOR6, or C(O)N(R6)2;
R2 and R3 are independently selected from the group consisting of O—(C0-C4 alkylene or haloalkylene), C1-C5 alkylene or haloalkylene, N(R6)—(C1-C4 alkylene or haloalkylene), -Ta-C1-C6 alkyl-Tb-, -Ta-N(Rs)-Tb, -Ta-O-Tb, -Ta-PEGn-O-Tb, -Ta-S—S-Tb, -Ta-S—S—S-Tb, -Ta-N(R)—N(Rs)-Tb-, -Ta-C2-C6 alkenyl-Tb-, -Ta-C2-C6 alkynyl-Tb-, -Ta-C(═O)-Tb—, -Ta-C(═CH2)-Tb—, -Ta-C(═O)—C(═O)-Tb-, -Ta—C(═O)—(C1-C6 alkyl)-C(═O)-Tb—, -Ta-C(═O)—(C3-C12 cycloalkyl)-C(═O)-Tb—, -Ta-C(═O)—(C1-C6 alkyl)-(C3-C12 cycloalkyl)-(C1-C6 alkyl)-C(═O)-Tb—, -Ta-C(═O)-(3- to 12-membered heterocycloalkyl)-C(═O)-Tb—, -Ta-C(═O)—(C1-C6 alkyl)-(3- to 12-membered heterocycloalkyl)-(C1-C6 alkyl)-C(═O)-Tb—, -Ta-C(═S)-Tb—, -Ta-S(═O)2-Tb—, -Ta-S(═O)-Tb—, -Ta-P(═O)(—ORs)-Tb-, -Ta-(C3-C12 cycloalkyl)-Tb-, -Ta-(C6-C12 aryl)-Tb-, -Ta-(3- to 12-membered heterocycloalkyl)-Tb-, or -Ta-(5- to 12-membered heteroaryl)-Tb-, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, C6-C12 aryl, 3- to 12-membered heterocycloalkyl, or 5- to 12-membered heteroaryl is optionally substituted with one or more deuterium, halo, —ORs, —N(Rs)2, or —C(═O)ORs;
PEGn is (—OCH2CH2—)n, n=1-8;
Ta and Tb each independently are absent, —N(Rs)—, —O—, C1-C6 alkyl, —N(Rs)—(C1-C6 alkyl)-, —(C1-C6 alkyl)-N(Rs)—, —N(Rs)—(C1-C6 alkyl)-N(Rs)—, —O—(C1-C6 alkyl)-, —(C1-C6 alkyl)-O—, or —O— (C1-C6 alkyl)-O—; wherein the C1-C6 alkyl is optionally substituted with one or more halogen; and
each Rs independently is H, deuterium or C, —C6 alkyl optionally substituted with one or more halogen;
each R4 is independently selected from the group consisting of H, deuterium, halogen, CN, OR6, N(R6)2, COOR6, C(O)N(R6)2, SO2R6, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkyl substituted by OR6, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkenyl substituted by OR6, C2-C6 alkynyl, C2-C6 haloalkynyl, C2-C6 alkynyl substituted by OR6, C3-C6 cycloalkyl, and a 3- to 6-membered heterocyclic ring including 1 to 2 ring members selected from the group consisting of O, S, and N(R6);
each R6 is independently selected from the group consisting of —H, deuterium, halogen, —NH2, —CN, —OH, —N3, —NO2, carboxyl, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, —C6-10 aryl, —C5-10 heteroaryl, C3-10 heterocyclic ring or C3-10 carbocyclic ring, and each of which is independently optionally substituted with deuterium, halogen, —NH2, —CN, —OH, —NO2, carbonyl, ═O, oxo, carboxyl, C1-6 alkoxy, or C1-6 alkyl; and each of the heteroaryl and heterocyclic ring contains at least one heteroatoms selected from N, O or S;
each X1 is independently selected from the group consisting of C═O, —CH2—, —CHF—, and —CF2—;
each X2 is independently selected from (C(R8)2)(1-3), NR8(C(R8)2)(1-3), —NH(C(R8)2)(1-3), —N(C1-6 alkyl)(C(R8)2)(1-3) or —N(haloC1-6 alkyl)(C(R8)2)(1-3); wherein each R8 is independently selected from the group consisting of H, deuterium, halogen, C1-C6 alkyl, CN, OR6, N(R6)2, C1-C6 haloalkyl, C3-C6 cycloalkyl, C1-C6 alkyl substituted by OR6, and C1-C6 alkyl substituted by N(R6)2; optionally 2 R8 on different carbon atoms may be taken together, along with the atoms to which they are attached, to form a 3- to 6-membered fused ring; and optionally 2 R8 on a single carbon atom may be taken together, along with the atom to which they are attached, to form a 3- to 6-membered spirocycle;
each X3 is independently selected from the group consisting of COOR6, C(O)SR6, C(S)OR6, SO2R6, C(O)N(R9)2,
and CN; and each R9 is independently selected from H, deuterium, COOR6, SO2R6, (CH2)1-3—C(═O)OR6, OR6, SR6, NH2, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, O(C1-C6 alkyl), O(C6-C10 aryl), O(C1-C6 alkyl)-OR6, S(C1-C6 alkyl), S(C6-C10 aryl), S(═O)2R6, S(═O)20R6, P(═O)(R6)2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-10 aryl, 3-8 membered heterocycloalkyl, or 3-10 membered heteroaryl.

### Claim 69 (depends on 68)

The compound or pharmaceutically acceptable salt thereof of claim 68, wherein
is independently selected from the group consisting of
independently selected from the group consisting of
is independently selected from the group consisting of

### Claim 70 (depends on 68)

The compound or pharmaceutically acceptable salt thereof of claim 68, wherein each R1 is independently selected from H, deuterium, halogen, OR6, N(R6)2, or C1-C6 alkyl; wherein the C1-C6 alkyl is optionally substituted with one or more deuterium, halogen, OR6, N(R6)2, COOR6, or C(O)N(R6)2;
R2 and R3 are independently selected from -Ta-C1-C6 alkyl-Tb-, -Ta-N(Rs)-Tb, -Ta-O-Tb, -Ta-PEGn-O-Tb, -Ta-S—S-Tb, -Ta-S—S—S-Tb, -Ta-N(Rs)—N(Rs)-Tb-, -Ta-C2-C6 alkenyl-Tb-, -Ta-C2-C6 alkynyl-Tb-, -Ta-C(═O)-Tb—, -Ta-C(═CH2)-Tb-, -Ta-C(═O)—C(═O)-Tb-, -Ta-C(═O)—(C1-C6 alkyl)-C(═O)-Tb—, -Ta-C(═O)—(C3-C12 cycloalkyl)-C(═O)-Tb—, -Ta-C(═O)—(C1-C6 alkyl)-(C3-C12 cycloalkyl)-(C1-C6 alkyl)-C(═O)-Tb—, -Ta-C(═O)-(3- to 12-membered heterocycloalkyl)-C(═O)-Tb—, -Ta-C(═O)—(C1-C6 alkyl)-(3- to 12-membered heterocycloalkyl)-(C1-C6 alkyl)-C(═O)-Tb—, -Ta-C(═S)-Tb—, -Ta-S(═O)2-Tb-, -Ta-S(═O)-Tb—, -Ta-P(═O)(—ORs)-Tb-, -Ta-(C3-C12 cycloalkyl)-Tb-, -Ta-(C6-C12 aryl)-Tb-, -Ta-(3- to 12-membered heterocycloalkyl)-Tb-, or -Ta-(5- to 12-membered heteroaryl)-Tb-, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, C6-C12 aryl, 3- to 12-membered heterocycloalkyl, or 5- to 12-membered heteroaryl is optionally substituted with one or more deuterium, halo, —ORs, —N(Rs)2, or —C(═O)ORs;
each R4 is independently selected from the group consisting of H, deuterium, F, Cl, Br, I, CN, OR6, N(R6)2, COOR6, C(O)N(R6)2, SO2R6, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkyl substituted by OR6, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkenyl substituted by OR6, C2-C6 alkynyl, C2-C6 haloalkynyl, C2-C6 alkynyl substituted by OR6, C3-C6 cycloalkyl, and a 3- to 6-membered heterocyclic ring including 1 to 2 ring members selected from the group consisting of O, S, and N(R6);
each R6 is independently selected from the group consisting of —H, deuterium, —F, —Cl, —Br, —I, —NH2, —CN, —OH, —N3, —NO2, carboxyl, C1-C3 alkyl, C1-C3 alkoxy, C2-C4 alkenyl, C2-C4 alkynyl, 6-membered aryl, 7-membered aryl, 8-membered aryl, 5-membered heteroaryl, 6-membered heteroaryl, 7-membered heteroaryl, 8-membered heteroaryl, 5-membered heterocyclic ring, 6-membered heterocyclic ring, 7-membered heterocyclic ring, 8-membered heterocyclic ring, 5-membered carbocyclic ring, 6-membered carbocyclic ring, 7-membered carbocyclic ring, or 8-membered carbocyclic ring, and each of which is independently optionally substituted with deuterium, —F, —Cl, —Br, —I, —NH2, —CN, —OH, —NO2, carbonyl, ═O, oxo, carboxyl, C1-C3 alkoxy, or C1-C3 alkyl; and each of the heteroaryl and heterocyclic ring contains 1 or 2 heteroatoms selected from N, O or S;
each X1 is independently selected from the group consisting of C═O, —CH2—, —CHF—, and —CF2—;
each X2 is independently selected from (C(R8)2)(1-3), wherein each R8 is independently selected from the group consisting of H, deuterium, halogen, C1-C6 alkyl, CN, OR6, N(R6)2, C1-C6 haloalkyl, C3-C6 cycloalkyl, C1-C6 alkyl substituted by OR6, and C1-C6 alkyl substituted by N(R6)2; optionally 2 R8 on different carbon atoms may be taken together, along with the atoms to which they are attached, to form a 3- to 6-membered fused ring; and optionally 2 R8 on a single carbon atom may be taken together, along with the atom to which they are attached, to form a 3- to 6-membered spirocycle;
each X3 is independently selected from the group consisting of COOR6, C(O)SR6, C(S)OR6, SO2R6, C(O)N(R9)2,
and CN;
each R9 is independently selected from the group consisting of H, deuterium, COOR6, and SO2R6.

### Claim 71 (depends on 68)

The compound or pharmaceutically acceptable salt thereof of claim 68, wherein each R1 is independently selected from the group consisting of H, deuterium, halogen, C1-C3 alkyl, CN and C1-C3 haloalkyl;
R2 and R3 are independently selected from -Ta-C1-C6 alkyl-Tb-, -Ta-N(Rs)-Tb, -Ta-O-Tb, -Ta-PEGn-O-Tb, -Ta-S—S-Tb, -Ta-S—S—S-Tb, -Ta-N(Rs)—N(Rs)-Tb-, -Ta-C2-C6 alkenyl-Tb-, -Ta-C2-C6 alkynyl-Tb-, -Ta-C(═O)-Tb—, -Ta-C(═CH2)-Tb-, -Ta-C(═O)—C(═O)-Tb-, -Ta-C(═O)—(C1-C6 alkyl)-C(═O)-Tb—, -Ta-C(═O)—(C3-C12 cycloalkyl)-C(═O)-Tb—, -Ta-C(═O)—(C1-C6 alkyl)-(C3-C12 cycloalkyl)-(C1-C6 alkyl)-C(═O)-Tb—, -Ta-C(═O)-(3- to 12-membered heterocycloalkyl)-C(═O)-Tb—, -Ta-C(═O)—(C1-C6 alkyl)-(3- to 12-membered heterocycloalkyl)-(C1-C6 alkyl)-C(═O)-Tb—, -Ta-C(═S)-Tb—, -Ta-S(═O)2-Tb-, -Ta-S(═O)-Tb—, -Ta-P(═O)(—ORs)-Tb-, -Ta-(C3-C12 cycloalkyl)-Tb-, -Ta-(C6-C12 aryl)-Tb-, -Ta-(3- to 12-membered heterocycloalkyl)-Tb-, or -Ta-(5- to 12-membered heteroaryl)-Tb-, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, C6-C12 aryl, 3- to 12-membered heterocycloalkyl, or 5- to 12-membered heteroaryl is optionally substituted with one or more deuterium, halo, —ORs, —N(Rs)2, or —C(═O)ORs; wherein in -Ta-(C3-C12 cycloalkyl)-Tb- or -Ta-(3- to 12-membered heterocycloalkyl)-Tb-, the C3-C12 cycloalkyl or 3- to 12-membered heterocycloalkyl is attached to Ta and Tb respectively via two different atoms of the C3-C12 cycloalkyl or 3- to 12-membered heterocycloalkyl;
PEGn is (—OCH2CH2—)n, n=1-8;
Ta and Tb each independently are absent, —N(Rs)—, —O—, C1-C6 alkyl, —N(Rs)—(C1-C6 alkyl)-, —(C1-C6 alkyl)-N(Rs)—, —N(Rs)—(C1-C6 alkyl)-N(Rs)—, —O—(C1-C6 alkyl)-, —(C1-C6 alkyl)-O—, or —O—(C1-C6 alkyl)-O—; wherein the C1-C6 alkyl is optionally substituted with one or more halogen; and
each Rs independently is H, deuterium, or C1-C6 alkyl optionally substituted with one or more halogen;
each R4 is independently selected from the group consisting of H, deuterium, F, Cl, Br, I, OH, C1-C3 alkyl, C1-C3 haloalkyl, OC1-C3 alkyl, OC1-C3 haloalkyl, C2-C3 alkenyl, C2-C3 alkynyl, and N(R6)2;
each R6 is independently selected from the group consisting of —H, deuterium, —F, —Cl, —Br, —I, —NH2, —CN, —OH, —N3, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, ethylene, 6-membered aryl, 5-membered heteroaryl, 6-membered heteroaryl, 5-membered heterocyclic ring, 6-membered heterocyclic ring, 5-membered carbocyclic ring, or 6-membered carbocyclic ring, and each of which is independently optionally substituted with deuterium, —F, —Cl, —Br, —I, —NH2, —CN, —OH, —NO2, carbonyl, ═O, oxo, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; and each of the heteroaryl and heterocyclic ring contains 1 or 2 heteroatoms selected from N, O or S;
each X1 is selected from the group consisting of C═O and —CH2—;
each X2 is CH2CHR8, where R8 is selected from the group consisting of H, deuterium, C1-C3 alkyl, C1-C3 alkyl substituted by OH, C1-C3 alkyl substituted by OC1-C3 alkyl, and C3-C6 cycloalkyl;
each X3 is independently selected from the group consisting of COOR6, SO2R6, C(O)N(R9)2,
and CN;
each R9 is independently H or deuterium.

### Claim 72 (depends on 68)

The compound or pharmaceutically acceptable salt thereof of claim 68, wherein each R1 is independently selected from the group consisting of H, deuterium, F, Cl, Br, CN and methyl;
R2 and R3 are independently selected from -Ta-C1-C6 alkyl-Tb-, -Ta-N(Rs)-Tb, -Ta-O-Tb, -Ta-PEGn-O-Tb, -Ta-S—S-Tb, -Ta-S—S—S-Tb, -Ta-N(Rs)—N(Rs)-Tb-, -Ta-C2-C6 alkenyl-Tb-, -Ta-C2-C6 alkynyl-Tb-, -Ta-C(═O)-Tb—, -Ta-C(═CH2)-Tb-, -Ta-C(═O)—C(═O)-Tb-, -Ta-C(═S)-Tb—, -Ta-S(═O)2-Tb-, -Ta-S(═O)-Tb—, -Ta-P(═O)(—ORs)-Tb-, -Ta-(C3-C12 cycloalkyl)-Tb-, -Ta-(C6-C12 aryl)-Tb-, -Ta-(3- to 12-membered heterocycloalkyl)-Tb-, or -Ta-(5- to 12-membered heteroaryl)-Tb-, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, C6-C12 aryl, 3- to 12-membered heterocycloalkyl, or 5- to 12-membered heteroaryl is optionally substituted with one or more deuterium, halo, —ORs, —N(Rs)2, or —C(═O)ORs;
each R4 independently is selected from the group consisting of H, deuterium, Br, Cl, OH, CH3, CH2CH3, CH═CH2, C≡CH, OCH3, OCFH2, OCF2H, OCF3, and N(R6)2;
each R6 is independently selected from the group consisting of H, —F, —Cl, —Br, —I, —NH2, —CN, —OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, CH2F, —CHF2, —CF3 and
each X1 is C═O;
each X2 is CH2CHR8, wherein R8 is selected from the group consisting of H, deuterium, CH3, CH2OH, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2OCH3, and cyclopropyl;
each X3 is independently selected from the group consisting of COOR6, C(O)N(R9)2,
and CN;
each R9 is independently H or deuterium.

### Claim 73 (depends on 68)

The compound or pharmaceutically acceptable salt thereof of claim 68, wherein each R1 is independently selected from the group consisting of H, deuterium, F, Cl, Br, CN and methyl;
R2 and R3 are independently selected from -Ta-C1-C6 alkyl-Tb-, -Ta-N(Rs)-Tb, -Ta-O-Tb, -Ta-PEGn-O-Tb, -Ta-S—S-Tb, -Ta-S—S—S-Tb, -Ta-N(Rs)—N(Rs)-Tb-, -Ta-C2-C6 alkenyl-Tb-, -Ta-C2-C6 alkynyl-Tb-, -Ta-C(═O)-Tb—, -Ta-C(═CH2)-Tb-, -Ta-C(═O)—C(═O)-Tb-, -Ta-C(═S)-Tb—, -Ta-S(═O)2-Tb-, -Ta-S(═O)-Tb—, -Ta-P(═O)(—ORs)-Tb-, -Ta-(C3-C12 cycloalkyl)-Tb-, -Ta-(C6-C12 aryl)-Tb-, -Ta-(3- to 12-membered heterocycloalkyl)-Tb-, or -Ta-(5- to 12-membered heteroaryl)-Tb-, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, C6-C12 aryl, 3- to 12-membered heterocycloalkyl, or 5- to 12-membered heteroaryl is optionally substituted with one or more deuterium, halo, —ORs, —N(Rs)2, or —C(═O)ORs; and wherein the C3-C12 cycloalkyl or 3- to 12-membered heterocycloalkyl is attached to Ta and Tb respectively via two different atoms of the C3-C12 cycloalkyl or 3- to 12-membered heterocycloalkyl;
PEGn is (—OCH2CH2—)n, n=1-8;
Ta and Tb each independently are absent, —N(Rs)—, —O—, C1-C6 alkyl, —N(Rs)—(C1-C6 alkyl)-, —(C1-C6 alkyl)-N(Rs)—, —N(Rs)—(C1-C6 alkyl)-N(Rs)—, —O—(C1-C6 alkyl)-, —(C1-C6 alkyl)-O—, or —O— (C1-C6 alkyl)-O—; wherein the C1-C6 alkyl is optionally substituted with one or more halogen; and each Rs independently is H, deuterium or C1-C6 alkyl optionally substituted with one or more halogen;
each R4 independently is selected from the group consisting of H, deuterium, Br, OH, CH3, CH2CH3, CH═CH2, C≡CH, OCH3, NH2 and NHCH3;
each R6 is independently selected from the group consisting of H, —F, —Cl, —Br, —I, —NH2, —CN, —OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, CH2F, —CHF2, —CF3 and
each X1 is C═O;
each X2 is CHR8CHR8, where each R8 is independently selected from the group consisting of H, deuterium, C1-C3 alkyl, C1-C3 alkyl substituted by OH, C1-C3 alkyl substituted by OC1-C3 alkyl, and C3-C6 cycloalkyl, and optionally the 2 R8 on different carbon atoms are taken together, along with the atoms to which they are attached, to form a 3- to 6-membered fused ring;
each X3 is independently selected from the group consisting of COOH, COOCH3, CONH2,
and CN;
each R9 is independently H or deuterium.

### Claim 74 (depends on 68)

The compound or pharmaceutically acceptable salt thereof of claim 68, wherein each R1 is independently selected from the group consisting of H, deuterium, F, Cl, Br, CN and methyl;
R2 and R3 are independently selected from O—(C1-C4 alkylene or haloalkylene)-C2-C6 alkenyl, C1-C5 alkylene or haloalkylene, (C1-C4 alkylene or haloalkylene)-N(R6), and N(R6)—(C1-C4 alkylene or haloalkylene)-C2-C6 alkenyl, —C0-6 alkyl-NH—C0-6 alkyl-, —C0-6 alkyl-N(C1-6 alkyl)-C0-6 alkyl-, —C0-6 alkyl-O—C0-6 alkyl-, —C0-6 alkyl-PEGn-O—C0-6 alkyl, —C0-6 alkyl-S—S—C0-6 alkyl, —C0-6 alkyl-S—S—S—C0-6 alkyl, —C0-6 alkyl-C2-C6 alkenyl-C0-6 alkyl-, —C0-6 alkyl-C2-C6 alkynyl-C0-6 alkyl-, —C0-6 alkyl-C(═O)—C0-6 alkyl-, —C0-6 alkyl-C(═CH2)—C0-6 alkyl-, —C0-6 alkyl-C(═O)—C(═O)—C0-6 alkyl-, —C0-6 alkyl-C(═S)—C0-6 alkyl-, —C0-6 alkyl-S(═O)2—C0-6 alkyl-, —C0-6 alkyl-S(═O)—C0-6 alkyl-, —C0-6 alkyl-P(═O)(—OH)—C0-6 alkyl-, —C0-6 alkyl-C3-C12 cycloalkyl-C0-6 alkyl-, —C0-6 alkyl-C6-C12 aryl-C0-6 alkyl-, —C0-6 alkyl-(3- to 12-membered heterocyclyl)-C0-6 alkyl-, —C0-6 alkyl-(5- to 12-membered heteroaryl)-C0-6 alkyl-, —C0-6 alkyl-O-(5- to 12-membered heteroaryl)-O—C0-6 alkyl-, —C0-6 alkyl-O—C(═O)—NH—C0-6 alkyl-, —C0-6 alkyl-O—C(═O)—C0-6 alkyl-, —C0-6 alkyl-NH—C(═O)—C0-6 alkyl-, —OC(═O)—O—, —NH—C(═O)—NH—, or —NH—C(═S)—NH—;
wherein the C2-C6 alkenyl, C2-C6 alkynyl, C3-C12 cycloalkyl, C6-C12 aryl, 3- to 12-membered heterocycloalkyl, or 5- to 12-membered heteroaryl is optionally substituted with one or more deuterium, halo, —ORs, —N(Rs)2, or —C(═O)ORs;
each R4 independently is selected from the group consisting of H, deuterium, Br, OH, CH3, CH2CH3, CH═CH2, C≡CH, OCH3, NH2 and NHCH3;
each R6 is independently selected from the group consisting of H, —F, —Cl, —Br, —I, —NH2, —CN, —OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, CH2F, —CHF2, —CF3 and
each X1 is C═O;
each X2 is CHR8CHR8, where each R8 is independently selected from the group consisting of H, deuterium and C1-C3 alkyl, and optionally the 2 R8 on different carbon atoms are taken together, along with the atoms to which they are attached, to form a 3- to 6-membered fused ring;
each X3 is independently selected from the group consisting of COOH, COOCH3, CONH2,
and CN;
each R9 is independently H or deuterium.

### Claim 75 (depends on 68)

The compound or pharmaceutically acceptable salt thereof of claim 68, wherein each R1 is independently selected from the group consisting of H, deuterium, F, Cl, Br, CN and methyl;
R2 and R3 are independently selected from -Ta-C2-C6 alkenyl-Tb-, -Ta-C(═O)-Tb—, -Ta-PEGn-O-Tb, -Ta—S—S-Tb, -Ta-S—S—S-Tb, -Ta-C(═CH2)-Tb-, or -Ta-(C6-C12 aryl)-Tb-, wherein the C2-C6 alkenyl or C6-C12 aryl is optionally substituted with one or more deuterium, halo, —ORs, —N(Rs)2, or —C(═O)ORs;
PEGn is (—OCH2CH2—)n, n=1-8;
Ta and Tb each independently are —N(Rs)—, —O—, —(C1-C6 alkyl)-O—, or —O—(C1-C6 alkyl)-O—;
wherein the C1-C6 alkyl it optionally substituted with one or more halogen; each Rs independently is H, deuterium or C1-C6 alkyl optionally substituted with one or more halogen;
each R4 independently is selected from the group consisting of H, deuterium, Br, OH, CH3, CH2CH3, CH═CH2, C≡CH, OCH3, NH2 and NHCH3;
each R6 is independently selected from the group consisting of H, —F, —Cl, —Br, —I, —NH2, —CN, —OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, CH2F, —CHF2, —CF3 and
each X1 is C═O;
each X2 is CH2C(R8)2, where each R8 is independently selected from the group consisting of H, deuterium, C1-C3 alkyl, C1-C3 alkyl substituted by OH, C1-C3 alkyl substituted by OC1-C3 alkyl, and C3-C6 cycloalkyl, and optionally the 2 R8 on a single carbon atom are taken together, along with the atoms to which they are attached, to form a 3- to 6-membered spirocycle;
each X3 is independently selected from the group consisting of COOH, COOCH3, CONH2,
and CN;
each R9 is independently H or deuterium.

### Claim 76 (depends on 68)

The compound or pharmaceutically acceptable salt thereof of claim 68, wherein each R1 is independently selected from the group consisting of H, deuterium, F, Cl, Br, CN and methyl;
R2-R3 is selected from
wherein:
each R5 is independently —OR7, NR7 or —C(O)OR7;
each R7 is independently hydrogen, deuterium or C1-2 alkyl; and
each R10 is independently hydrogen, deuterium, C1-2 alkyl or halogen;
each R4 independently is selected from the group consisting of H, deuterium, Br, OH, CH3, CH2CH3, CH═CH2, C≡CH, OCH3, NH2 and NHCH3;
each R6 is independently selected from the group consisting of H, —F, —Cl, —Br, —I, —NH2, —CN, —OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, CH2F, —CHF2, —CF3 and
each X1 is C═O;
each X2 is CH2C(R8)2, where each R8 is independently selected from the group consisting of H, deuterium and C1-C3 alkyl, and optionally the 2 R8 on a single carbon atom are taken together, along with the atoms to which they are attached, to form a 3- to 6-membered spirocycle;
each X3 is independently selected from the group consisting of COOH, COOCH3, CONH2,
and CN;
each R9 is independently H or deuterium.

### Claim 77 (depends on 76)

The compound or pharmaceutically acceptable salt thereof of claim 76, wherein each
R7 is independently hydrogen, deuterium or methyl;
each R10 is independently hydrogen, deuterium, methyl or fluorine; or
one R10 is hydrogen, and the other R10 is methyl or fluorine.

### Claim 78 (depends on 68)

The compound or pharmaceutically acceptable salt thereof of claim 68, wherein each R1 is independently selected from the group consisting of H, deuterium, F, Cl, Br, CN and methyl;
R2-R3 is selected from —(CH2)2-8—, —O(CH2)1-7—, —O(CH2)1-6O—, —OCH2CH(CH3)CH2O—, —OCH(CH3)CH2CH(CH3)O—,
—NH(CH2)1-7—, —(CH2)1-6NH(CH2)1-6—, —(CH2)1-6N(CH3)(CH2)1-6—, —NH(CH2)1-6O—, —NH—CO—NH—, —N(CH3)CO—NH—,
each R4 independently is selected from the group consisting of H, deuterium, Br, OH, CH3, CH2CH3, CH═CH2, C═CH, OCH3, NH2 and NHCH3;
each R6 is independently selected from the group consisting of H, —F, —Cl, —Br, —I, —NH2, —CN, —OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, CH2F, —CHF2, —CF3 and
each X1 is C═O;
each X2 is CH2C(R8)2, where each R8 is independently selected from the group consisting of H, deuterium and C1-C3 alkyl, and optionally the 2 R8 on a single carbon atom are taken together, along with the atoms to which they are attached, to form a 3- to 6-membered spirocycle;
each X3 is independently selected from the group consisting of COOH, COOCH3, CONH2,
and CN;
each R9 is independently H or deuterium.

### Claim 79 (depends on 68)

The compound or pharmaceutically acceptable salt thereof of claim 68, wherein each R1 is independently selected from the group consisting of H, deuterium, F, Cl, Br, CN and methyl;
R2-R3 is selected from —(CH2)2—, —(CH2)3—, —(CH2)4—, —(CH2)5—, —O(CH2)2—, —O(CH2)3—, —O(CH2)4—, —O(CH2)2O—, —O(CH2)3O—, —O(CH2)4O—, —OCH2CH(CH3)CH2O—, —OCH(CH3)CH2CH(CH3)O—,
—O(CH2)4O—, —O(CH2)5O—, —NH(CH2)2—, —NH(CH2)3—, —NH(CH2)4—, —(CH2)2NH—, —(CH2)3NH—, —(CH2)4NH—, —CH2NHCH2—, —CH2N(CH3)CH2—, —NH(CH2)3O—, —NH—CO—NH—,
or —N(CH3)CONH—;
each R4 independently is selected from the group consisting of H, deuterium, Br, OH, CH3, CH2CH3, CH═CH2, C≡CH, OCH3, NH2 and NHCH3;
each R6 is independently selected from the group consisting of H, —F, —Cl, —Br, —I, —NH2, —CN, —OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, CH2F, —CHF2, —CF3 and
each X1 is C═O;
each X2 is CH2C(R8)2, where each R8 is independently selected from the group consisting of H, deuterium and C1-C3 alkyl, and optionally the 2 R8 on a single carbon atom are taken together, along with the atoms to which they are attached, to form a 3- to 6-membered spirocycle;
each X3 is independently selected from the group consisting of COOH, COOCH3, CONH2,
and CN;
each R9 is independently H or deuterium.

### Claim 80 (depends on 68)

The compound or pharmaceutically acceptable salt thereof of claim 68, wherein the compound is of general formula I-1,
wherein each R1, R2, R3, R4, X1, X2 and X3 are as defined in claim 68.

### Claim 81 (depends on 68)

The compound or pharmaceutically acceptable salt thereof of claim 68, wherein the compound is
1.
4,4′-((propane-1,3-diylbis(oxy))bis(6-methoxyisoindoline-5,2-diyl))bis(4-oxobutanoic acid)
2.
4-(6-(3-((2-(3-carboxypropanoyl)-6-methoxyisoindolin-5-yl)oxy)propoxy)-4-fluoro-5-
methoxyisoindolin-2-yl)-4-oxobutanoic acid
3.
sodium (S)-4-(5-(3-((2-(3-carboxylatopropanoyl)-6-methoxyisoindolin-5-yl)oxy)propoxy)-6-
methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoate
4.
4-(5-(3-((2-(3-carboxypropanoyl)-4-fluoro-6-methoxyisoindolin-5-yl)oxy)propoxy)-6-
methoxyisoindolin-2-yl)-4-oxobutanoic acid
5.
4,4′-((propane-1,3-diylbis(oxy))bis(3-methoxy-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-2,6-
diyl))bis(4-oxobutanoic acid)
6.
4-(5-(3-((2-(4-ethoxy-4-oxobutanoyl)-6-methoxyisoindolin-5-yl)oxy)propoxy)-6-
methoxyisoindolin-2-yl)-4-oxobutanoic acid
7.
4,4′-(((methylazanediyl)bis(methylene))bis(6-methoxyisoindoline-5,2-diyl))bis(4-
oxobutanoic acid)
8.
4-(5-(3-((2-(3-carboxypropanoyl)-4-chloro-6-methoxyisoindolin-5-yl)oxy)propoxy)-6-
methoxyisoindolin-2-yl)-4-oxobutanoic acid
9.
4,4′-((propane-1,3-diylbis(oxy))bis(4-fluoro-6-methoxyisoindoline-5,2-diyl))bis(4-
oxobutanoic acid)
10.
4,4′-(((2-methylenepropane-1,3-diyl)bis(oxy))bis(6-methoxyisoindoline-5,2-diyl))bis(4-
oxobutanoic acid)
11.
4,4′-(((2-methylenepropane-1,3-diyl)bis(oxy))bis(4-chloro-6-methoxyisoindoline-5,2-
diyl))bis(4-oxobutanoic acid)
12.
4,4′-((propane-1,3-diylbis(oxy))bis(4-chloro-6-methoxyisoindoline-5,2-diyl))bis(4-
oxobutanoic acid)
13.
4-(5-(3-((2-(3-carboxypropanoyl)-4-chloro-6-methoxyisoindolin-5-yl)oxy)propoxy)-4-
fluoro-6-methoxyisoindolin-2-yl)-4-oxobutanoic acid
14.
4-(5-(3-((2-((2-carboxyethyl)carbamoyl)-6-methoxyisoindolin-5-yl)oxy)propoxy)-6-
methoxyisoindolin-2-yl)-4-oxobutanoic acid
15.
4,4′-((propane-1,3-diylbis(oxy))bis(6-methoxyisoindoline-5,2-diyl))bis(2-methyl-4-
oxobutanoic acid)
16.
(2S,2′S)-4,4′-((propane-1,3-diylbis(oxy))bis(6-methoxyisoindoline-5,2-diyl))bis(2-methyl-4-
oxobutanoic acid)
17.
(S)-4-(5-(3-((2-(3-carboxypropanoyl)-6-methoxyisoindolin-5-yl)oxy)propoxy)-6-
methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
18.
(2S,2′S)-4,4′-((ethane-1,2-diylbis(oxy))bis(6-methoxyisoindoline-5,2-diyl))bis(2-methyl-4-
oxobutanoic acid)
19.
(2S,2′S)-4,4′-((butane-1,4-diylbis(oxy))bis(6-methoxyisoindoline-5,2-diyl))bis(2-methyl-4-
oxobutanoic acid)
20.
(2S,2′S)-4,4′-((pentane-1,5-diylbis(oxy))bis(6-methoxyisoindoline-5,2-diyl))bis(2-methyl-4-
oxobutanoic acid)
21.
(S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-6-methoxyisoindolin-5-yl)oxy)propyl)-6-
methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
22.
(S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-6-methoxyisoindolin-5-yl)amino)propoxy)-6-
methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
23.
(S)-4-(5-(4-((2-((S)-3-carboxybutanoyl)-6-methoxyisoindolin-5-yl)amino)butyl)-6-
methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
24.
(2S,2′S)-4,4′-(propane-1,3-diylbis(6-methoxyisoindoline-5,2-diyl))bis(2-methyl-4-
oxobutanoic acid)
25.
(2S,2′S)-4,4′-(pentane-1,5-diylbis(6-methoxyisoindoline-5,2-diyl))bis(2-methyl-4-
oxobutanoic acid)
26.
(2S,2′S)-4,4′-((pentane-2,4-diylbis(oxy))bis(6-methoxyisoindoline-5,2-diyl))bis(2-methyl-4-
oxobutanoic acid)
27.
(2S,2′S)-4,4′-(((2,2-dimethylpropane-1,3-diyl)bis(oxy))bis(6-methoxyisoindoline-5,2-
diyl))bis(2-methyl-4-oxobutanoic acid)
28.
(2S,2′S)-4,4′-(((cyclopropane-1,1-diylbis(methylene))bis(oxy))bis(6-methoxyisoindoline-5,2-
diyl))bis(2-methyl-4-oxobutanoic acid)
29.
(S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-6-methoxy-4-methylisoindolin-5-yl)oxy)propoxy)-
6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
30.
(S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-4-fluoro-6-methoxyisoindolin-5-yl)oxy)propoxy)-6-
methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
31.
(S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-4-chloro-6-methoxyisoindolin-5-yl)oxy)propoxy)-6-
methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
32.
(S)-4-(5-(3-((4-bromo-2-((S)-3-carboxybutanoyl)-6-methoxyisoindolin-5-yl)oxy)propoxy)-6-
methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
33.
(S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-6-methoxy-4,7-dimethylisoindolin-5-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
34.
(S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-6-methoxyisoindolin-5-yl)oxy)propoxy)-7-fluoro-6-
methoxy-4-methylisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
35.
(S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-6-methoxyisoindolin-5-yl)oxy)propoxy)-7-chloro-6-
methoxy-4-methylisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
36.
(S)-4-(5-(3-((7-bromo-2-((S)-3-carboxybutanoyl)-6-methoxy-4-methylisoindolin-5-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
37.
(S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-4,7-difluoro-6-methoxyisoindolin-5-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
38.
(S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-6-methoxyisoindolin-5-yl)oxy)propoxy)-7-chloro-4-
fluoro-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
39.
(S)-4-(5-(3-((7-bromo-2-((S)-3-carboxybutanoyl)-4-fluoro-6-methoxyisoindolin-5-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
40.
(S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-4-fluoro-6-methoxy-7-methylisoindolin-5-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
41.
(S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-4-chloro-6-methoxy-7-methylisoindolin-5-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
42.
(S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-4-chloro-7-fluoro-6-methoxyisoindolin-5-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
43.
(S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-4,7-dichloro-6-methoxyisoindolin-5-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
44.
(S)-4-(5-(3-((7-bromo-2-((S)-3-carboxybutanoyl)-4-chloro-6-methoxyisoindolin-5-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
45.
(S)-4-(5-(3-((4-bromo-2-((S)-3-carboxybutanoyl)-6-methoxy-7-methylisoindolin-5-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
46.
(S)-4-(5-(3-((4-bromo-2-((S)-3-carboxybutanoyl)-7-fluoro-6-methoxyisoindolin-5-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
47.
(S)-4-(5-(3-((4-bromo-2-((S)-3-carboxybutanoyl)-7-chloro-6-methoxyisoindolin-5-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
48.
(S)-4-(5-(3-((4,7-dibromo-2-((S)-3-carboxybutanoyl)-6-methoxyisoindolin-5-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
49.
(2S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-6-methoxy-3,4-dimethylisoindolin-5-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
50.
(2S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-4-fluoro-6-methoxy-3-methylisoindolin-5-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
51.
(2S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-4-chloro-6-methoxy-3-methylisoindolin-5-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
52.
(2S)-4-(5-(3-((4-bromo-2-((S)-3-carboxybutanoyl)-6-methoxy-3-methylisoindolin-5-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
53.
(2S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-6-methoxy-3,4,7-trimethylisoindolin-5-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
54.
(2S)-4-(6-(3-((2-((S)-3-carboxybutanoyl)-6-methoxyisoindolin-5-yl)oxy)propoxy)-4-fluoro-
5-methoxy-1,7-dimethylisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
55.
(2S)-4-(6-(3-((2-((S)-3-carboxybutanoyl)-6-methoxyisoindolin-5-yl)oxy)propoxy)-4-chloro-
5-methoxy-1,7-dimethylisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
56.
(2S)-4-(5-(3-((7-bromo-2-((S)-3-carboxybutanoyl)-6-methoxy-3,4-dimethylisoindolin-5-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
57.
(2S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-4,7-difluoro-6-methoxy-3-methylisoindolin-5-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
58.
(2S)-4-(6-(3-((2-((S)-3-carboxybutanoyl)-6-methoxyisoindolin-5-yl)oxy)propoxy)-4-chloro-
7-fluoro-5-methoxy-1-methylisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
59.
(2S)-4-(5-(3-((7-bromo-2-((S)-3-carboxybutanoyl)-4-fluoro-6-methoxy-3-methylisoindolin-
5-yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
60.
(2S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-4-fluoro-6-methoxy-3,7-dimethylisoindolin-5-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
61.
(2S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-4-chloro-6-methoxy-3,7-dimethylisoindolin-5-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
62.
(2S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-4-chloro-7-fluoro-6-methoxy-3-methylisoindolin-
5-yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
63.
(2S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-4,7-dichloro-6-methoxy-3-methylisoindolin-5-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
64.
(2S)-4-(5-(3-((7-bromo-2-((S)-3-carboxybutanoyl)-4-chloro-6-methoxy-3-methylisoindolin-
5-yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
65.
(2S)-4-(5-(3-((4-bromo-2-((S)-3-carboxybutanoyl)-6-methoxy-3,7-dimethylisoindolin-5-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
66.
(2S)-4-(5-(3-((4-bromo-2-((S)-3-carboxybutanoyl)-7-fluoro-6-methoxy-3-methylisoindolin-
5-yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
67.
(2S)-4-(5-(3-((4-bromo-2-((S)-3-carboxybutanoyl)-7-chloro-6-methoxy-3-methylisoindolin-
5-yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
68.
(2S)-4-(5-(3-((4,7-dibromo-2-((S)-3-carboxybutanoyl)-6-methoxy-3-methylisoindolin-5-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
69.
(2S)-4-(6-(3-((2-((S)-3-carboxybutanoyl)-4-fluoro-6-methoxyisoindolin-5-yl)oxy)propoxy)-
5-methoxy-1-methylisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
70.
(2S,2′S)-4,4′-((propane-1,3-diylbis(oxy))bis(4-fluoro-6-methoxyisoindoline-5,2-diyl))bis(2-
methyl-4-oxobutanoic acid)
71.
(S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-4-chloro-6-methoxyisoindolin-5-yl)oxy)propoxy)-4-
fluoro-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
72.
(S)-4-(6-(3-((2-((S)-3-carboxybutanoyl)-4-fluoro-6-methoxyisoindolin-5-yl)oxy)propoxy)-4-
chloro-5-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
73.
(S)-4-(6-(3-((2-((S)-3-carboxybutanoyl)-4-chloro-6-methoxyisoindolin-5-yl)oxy)propoxy)-4-
chloro-5-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
74.
(S)-4-(6-(3-((2-((S)-3-carboxybutanoyl)-4-chloro-6-methoxyisoindolin-5-yl)oxy)propoxy)-4-
fluoro-5-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
75.
(S)-4-(6-(3-((2-((S)-3-carboxybutanoyl)-6-methoxyisoindolin-5-yl)oxy)propoxy)-4-chloro-5-
methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
76.
(S)-4-(6-(3-((2-((S)-3-carboxybutanoyl)-6-methoxyisoindolin-5-yl)oxy)propoxy)-4-fluoro-5-
methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
77.
(S)-4-(5-(3-((6-((S)-3-carboxybutanoyl)-3-methoxy-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-2-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
78.
(S)-4-(5-(3-((6-((S)-3-carboxybutanoyl)-3-methoxy-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-2-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
79.
(2S,2′S)-4,4′-((propane-1,3-diylbis(oxy))bis(3-methoxy-5,7-dihydro-6H-pyrrolo[3,4-
b]pyridine-2,6-diyl))bis(2-methyl-4-oxobutanoic acid)
80.
(S)-4-(2-(3-((6-((S)-3-carboxybutanoyl)-2-methoxy-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-3-
yl)oxy)propoxy)-3-methoxy-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-methyl-4-
oxobutanoic acid
81.
(2S,2′S)-4,4′-((propane-1,3-diylbis(oxy))bis(2-methoxy-5,7-dihydro-6H-pyrrolo[3,4-
b]pyridine-3,6-diyl))bis(2-methyl-4-oxobutanoic acid)
82.
(S)-4-(5-(3-((6-((S)-3-carboxybutanoyl)-2-methoxy-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-3-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
83.
(2S,2′S)-4,4′-(1,3,7,8,11,13,17,18-octahydro-2H,6H,12H,16H-
[1,4,8,11]tetraoxacyclotetradecino[2,3-f:9,10-f′]diisoindole-2,12-diyl)bis(2-methyl-4-
oxobutanoic acid)
84.
(S)-4-(5-methoxy-6-(3-((6-methoxy-2-((S)-3-methyl-4-(methylsulfonamido)-4-
oxobutanoyl)isoindolin-5-yl)oxy)propoxy)isoindolin-2-yl)-2-methyl-4-oxobutanoic acid
85.
(S)-4-(5-(3-((2-((S)-4-((N,N-dimethylsulfamoyl)amino)-3-methyl-4-oxobutanoyl)-6-
methoxyisoindolin-5-yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic
acid
86.
4,4′-((propane-1,3-diylbis(oxy))bis(6-methoxyisoindoline-5,2-diyl))bis(4-oxobutanenitrile)
87.
(S)-4-(5-(3-((2-(3-cyanopropanoyl)-6-methoxyisoindolin-5-yl)oxy)propoxy)-6-
methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
88.
(1R,2R)-2-(5-(3-((2-((S)-3-carboxybutanoyl)-6-methoxyisoindolin-5-yl)oxy)propoxy)-6-
methoxyisoindoline-2-carbonyl)cyclobutane-1-carboxylic acid
89.
(1R,2R)-2-(5-(3-((2-((S)-3-carboxybutanoyl)-6-methoxyisoindolin-5-yl)oxy)propoxy)-6-
methoxyisoindoline-2-carbonyl)cyclopropane-1-carboxylic acid
90.
(1S,2S)-2-(5-(3-((2-((1R,2R)-2-carboxycyclopropane-1-carbonyl)-6-methoxyisoindolin-5-
yl)oxy)propoxy)-6-methoxyisoindoline-2-carbonyl)cyclopropane-1-carboxylic acid
91.
(S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-6-methoxyisoindolin-4-yl)oxy)propoxy)-6-
methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
92.
(S)-4-(5-(4-(2-((S)-3-carboxybutanoyl)-6-methoxyisoindolin-4-yl)butoxy)-6-
methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
93.
(S)-4-(5-(4-((2-((S)-3-carboxybutanoyl)-6-methoxyisoindolin-4-yl)oxy)butyl)-6-
methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
94.
(S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-6-methoxyisoindolin-5-yl)oxy)propoxy)-6-
methylisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
95.
(S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-6-ethylisoindolin-5-yl)oxy)propoxy)-6-
methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
96.
(S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-6-methoxyisoindolin-5-yl)oxy)propoxy)-6-
vinylisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
97.
(S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-6-ethynylisoindolin-5-yl)oxy)propoxy)-6-
methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
98.
(S)-4-(5-(3-((6-amino-2-((S)-3-carboxybutanoyl)isoindolin-5-yl)oxy)propoxy)-6-
methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
99.
(S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-6-(methylamino)isoindolin-5-yl)oxy)propoxy)-6-
methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
100.
(S)-4-(5-(3-((6-bromo-2-((S)-3-carboxybutanoyl)isoindolin-5-yl)oxy)propoxy)-6-
methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
101.
(S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-4-fluoro-6-methoxyisoindolin-5-yl)oxy)propoxy)-6-
hydroxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
102.
(S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-4-chloro-6-methoxyisoindolin-5-yl)oxy)propoxy)-6-
hydroxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
103.
(S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-4-fluoro-6-hydroxyisoindolin-5-yl)oxy)propoxy)-4-
fluoro-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
104.
(S)-4-(6-(3-((2-((S)-3-carboxybutanoyl)-4-fluoro-6-hydroxyisoindolin-5-yl)oxy)propoxy)-4-
fluoro-5-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
105.
(S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-4-chloro-6-hydroxyisoindolin-5-yl)oxy)propoxy)-4-
fluoro-6-methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
106.
(S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-4-chloro-6-methoxyisoindolin-5-yl)oxy)propoxy)-4-
fluoro-6-hydroxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
107.
(S)-4-(5-(3-((2-((S)-3-carboxybutanoyl)-4-fluoro-6-hydroxyisoindolin-5-yl)oxy)propoxy)-6-
methoxyisoindolin-2-yl)-2-methyl-4-oxobutanoic acid
108.
4,4′-((azanediylbis(methylene))bis(6-methoxyisoindoline-5,2-diyl))bis(4-oxobutanoic acid)
109.
4,4′-((propane-1,3-diylbis(oxy))bis(2-methoxy-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-3,6-
diyl))bis(4-oxobutanoic acid)
110.
4-(2-(3-((6-(3-carboxypropanoyl)-2-methoxy-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-3-
yl)oxy)propoxy)-3-methoxy-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxobutanoic acid
111.
4-(5-(3-((6-(3-carboxypropanoyl)-3-methoxy-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-2-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-4-oxobutanoic acid
112.
4-(5-(3-((6-(3-carboxypropanoyl)-2-methoxy-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-3-
yl)oxy)propoxy)-6-methoxyisoindolin-2-yl)-4-oxobutanoic acid
113.
4-(2-(3-((6-(4-(((4R,5R)-5-hydroxy-1,2-dithian-4-yl)oxy)-4-oxobutanoyl)-3-methoxy-6,7-
dihydro-5H-pyrrolo[3,4-b]pyridin-2-yl)oxy)propoxy)-3-methoxy-5,7-dihydro-6H-
pyrrolo[3,4-b]pyridin-6-yl)-4-oxobutanoic acid
114.
4-(5-((2-(((2-(3-carboxypropanoyl)-6-methoxy-2H-isoindol-5-yl)oxy)methyl)allyl)oxy)-6-
methoxyisoindolin-2-yl)-4-oxobutanoic acid
115.
4-(5-((2-(((2-(3-carboxypropanoyl)-6-methoxy-1H-indol-5-yl)oxy)methyl)allyl)oxy)-6-
methoxyisoindolin-2-yl)-4-oxobutanoic acid
116.
4-(5-((2-(((2-(3-carboxypropanoyl)-6-methoxy-1H-inden-5-yl)oxy)methyl)allyl)oxy)-6-
methoxyisoindolin-2-yl)-4-oxobutanoic acid
117.
4-(5-(3-((2-(3-carboxypropanoyl)-6-methoxy-2H-isoindol-5-yl)oxy)propoxy)-6-
methoxyisoindolin-2-yl)-4-oxobutanoic acid
118.
4-(5-(3-((2-(3-carboxypropanoyl)-6-methoxy-1H-indol-5-yl)oxy)propoxy)-6-methoxyisoindolin-
2-yl)-4-oxobutanoic acid
119.
4-(5-(3-((2-(3-carboxypropanoyl)-6-methoxy-1H-inden-5-yl)oxy)propoxy)-6-methoxyisoindolin-
2-yl)-4-oxobutanoic acid
120.
4-(5-(3-((2-(3-carboxypropanoyl)-4-fluoro-6-methoxyisoindolin-5-yl)oxy)propoxy)-6-methoxy-
2H-isoindol-2-yl)-4-oxobutanoic acid
121.
4-(5-(3-((2-(3-carboxypropanoyl)-4-fluoro-6-methoxyisoindolin-5-yl)oxy)propoxy)-6-methoxy-
1H-indol-2-yl)-4-oxobutanoic acid
122.
4-(5-(3-((2-(3-carboxypropanoyl)-4-fluoro-6-methoxyisoindolin-5-yl)oxy)propoxy)-6-methoxy-
1H-inden-2-yl)-4-oxobutanoic acid
123.
4-(5-(3-((2-(3-carboxypropanoyl)-4-fluoro-6-methoxy-2H-isoindol-5-yl)oxy)propoxy)-6-
methoxyisoindolin-2-yl)-4-oxobutanoic acid
124.
4-(5-(3-((2-(3-carboxypropanoyl)-4-fluoro-6-methoxy-1H-indol-5-yl)oxy)propoxy)-6-
methoxyisoindolin-2-yl)-4-oxobutanoic acid
125.
4-(5-(3-((2-(3-carboxypropanoyl)-4-fluoro-6-methoxy-1H-inden-5-yl)oxy)propoxy)-6-
methoxyisoindolin-2-yl)-4-oxobutanoic acid
126.
4-(5-(3-((2-(3-carboxypropanoyl)-4-fluoro-6-methoxy-2H-isoindol-5-yl)oxy)propoxy)-4-fluoro-
6-methoxyisoindolin-2-yl)-4-oxobutanoic acid
127.
4-(5-(3-((2-(3-carboxypropanoyl)-4-fluoro-6-methoxy-1H-indol-5-yl)oxy)propoxy)-4-fluoro-6-
methoxyisoindolin-2-yl)-4-oxobutanoic acid
128.
4-(5-(3-((2-(3-carboxypropanoyl)-4-fluoro-6-methoxy-1H-inden-5-yl)oxy)propoxy)-4-fluoro-6-
methoxyisoindolin-2-yl)-4-oxobutanoic acid.

### Claim 82 (depends on 68)

A pharmaceutical composition comprising a therapeutically effective amount of at least one compound or pharmaceutically acceptable salt thereof of claim 68 and at least one pharmaceutically acceptable excipient.

### Claim 83 (depends on 82)

The pharmaceutical composition of claim 82, wherein, the said compound or pharmaceutically acceptable salt thereof is in a weight ratio to the said excipient within the range from about 0.0001 to about 10.

### Claim 84 (depends on 82)

The pharmaceutical composition of claim 82, further comprising at least one of additional active agents selected from STING agonist compounds, anti-viral compounds, antigens, adjuvants, CTLA-4 and PD-1 pathway antagonists and other immunomodulatory agents, lipids, liposomes, peptides, anti-cancer agents, and chemotherapeutic agents.

### Claim 85 (depends on 68)

A method of inducing an immune response in a subject, or inducing STING-dependent type I interferon production in a subject; or a STING-dependent cytokine production in a subject; or
treating a cell proliferation disorder in a subject, said method comprising administering a therapeutically effective amount of a compound according to claim 68, or a pharmaceutically acceptable salt thereof, to the subject.

### Claim 86 (depends on 82)

A method of inducing an immune response in a subject, or inducing STING-dependent type I interferon production in a subject; or inducing a STING-dependent cytokine production in a subject; or treating a cell proliferation disorder in a subject, said method comprising administering a therapeutically effective amount of a pharmaceutical composition of claim 82, to the subject.

### Claim 87 (depends on 85)

The method of claim 85, wherein the cell proliferation disorder is cancer.
